ID   TMhep39
AC   CVCL_B6DP
SY   TMHepTG3960 x 2984 x 4912 39; TMHepTG3960 x 2984 x 4912 line 39
DR   Wikidata; Q112041797
RX   Patent=US5814716;
RX   PubMed=1369183;
CC   Characteristics: Established from a triple transgenic mice that contains 1) a human SERPINA1 promoter driving the expression of a mouse Myc as well as a second SERPINA1 promoter in front of a full copy of SERPINA1, 2) a human SERPINA1 promoter driving the expression of SV40 T-antigen and 3) a human F9 promoter driving the expression of F9 (PubMed=1369183).
CC   Genetic integration: Method=Transgenic mouse; Gene=HGNC; HGNC:3551; F9.
CC   Genetic integration: Method=Transgenic mouse; Gene=HGNC; HGNC:8941; SERPINA1.
CC   Genetic integration: Method=Transgenic mouse; Gene=MGI; MGI:97250; Myc.
CC   Transformant: Myc.
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
CC   Breed/subspecies: C57BL/6 x SJL transgenic TG3960 x TG2984 x TG4912.
DI   NCIt; C38756; Hepatocellular carcinoma of the mouse
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
CA   Cancer cell line
DT   Created: 17-03-22; Last updated: 19-12-24; Version: 6
//
RX   Patent=US5814716;
RA   Jallat S., Meulien P., Pavirani A., Perraud F.;
RT   "Cell lines from a transgenic mouse which express biologically active
RT   IX factor.";
RL   Patent number US5814716, 29-Sep-1998.
//
RX   PubMed=1369183; DOI=10.1007/BF02521733;
RA   Perraud F., Dalemans W., Ali-Hadji D., Pavirani A.;
RT   "Novel cell lines derived from transgenic mice expressing recombinant
RT   human proteins. Transgenic hepatoma-derived cell lines.";
RL   Cytotechnology 9:69-75(1992).
//